Shen Min Clinical Trials

Evidence supporting claims regarding the effectiveness of the Shen Min hair loss treatment.

CLINICAL TRIALS

More than 9 in 10 subjects taking the products in a six month double-blind, placebo controlled clinical trial report hair loss improvement using Shen Min product.

Bangor, Maine, August 2002 ­ Important new findings from a preliminary clinical trial of the product, a two component herbal supplement designed to reduce hair loss and promote healthy hair, were announced today. Subjects who completed the clinical trial and took the product demonstrated statistical improvement over placebo groups in hair thickness, perceived appearance, and hair loss improvement at both the three (3) and six (6) month intervals.

Specifically, more than nine-in-ten (92.3%) of the subjects that completed the clinical trial reported hair loss improvement. Additional top-line findings of those subjects completing the clinical trial include:

Perceived Appearance: More than three-fourths (76.9%) of the subjects taking the product reported some level of improvement in their perceived appearance compared to fourteen percent (14.3%) taking the placebo.

Thickness: More than three-in-four subjects (77.0%) taking it reported some level of improvement. Additionally, there were indications that actual hair growth was attained but the manufacturer is awaiting a second trial to affirm those results.

Approximately 90% of the subjects taking Shen Min were "happy" or "extremely happy" with the product.

Two-thirds of subjects taking it reported that they would continue to use the product while approximately thirty percent (31%) were uncertain. More than six-in-ten subjects taking Shen Min reported that they would recommend the product to others.

About the Clinical Trial: The prospective, randomized, double-blinded placebo controlled clinical trial was conducted by Marshall-Blum, LLC, for BioTech Corporation. The clinical trial, which surpassed Institutional Review Board design requirements, was limited to women between the ages 40-60. Twenty-six (26) and seven (7) subjects completed the trial on product and placebo, respectively.

Return to Shen Min Factfinder

Back to top